Circulating Tumor Cells (CTCs): Tracking the Spread of Cancer
Recently, a study was published in JAMA Oncology which was one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved survival.
Dr. Allan is a national leader in the study of circulating tumor cells, which were identified in the study. Her lab, at the Lawson Health Research Institute, has developed unique blood tests to track metastasis by measuring the number of CTCs in a patient’s blood stream.
Watch to find out how the CELLSEARCH® Circulating Tumor Cell (CTC) Test and the London Regional Cancer Program (Canada) helps to inform clinical decisions in patients with metastatic breast, prostate and colorectal cancer.